Instil Bio Inc. and ImmuneOnco Biopharmaceuticals have announced updates regarding the clinical trials of their bispecific antibody, '2510, for the treatment of non-small cell lung cancer (NSCLC). The companies revealed that a Phase 3 trial of '2510 in combination with chemotherapy for first-line NSCLC is anticipated to commence in mid-2026 in China, contingent upon regulatory discussions. Meanwhile, a U.S. monotherapy dose optimization Phase 1b/2 trial for relapsed/refractory solid tumors is expected to start before the end of 2025, pending regulatory approvals. This trial aims to align the dosing with ongoing trials in China and replaces a previously planned U.S. trial combining '2510 with chemotherapy for first-line NSCLC. Furthermore, ImmuneOnco plans to share initial safety and efficacy results from a Phase 2 trial in China during the second half of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。